
Sign up to save your podcasts
Or


Join Dr. Robert Gish in this insightful episode as he discusses the latest breakthrough in Wilson disease treatment: Cuvrior. This innovative medication offers a new option for patients with Wilson disease, featuring a remarkable safety profile, the convenience of no refrigeration, and future possibility of once-a-day dosing (research in progress). Dr. Gish explores how Cuvrior is revolutionizing care with its potential to be more affordable than traditional treatments like trientine, depending on insurance and contracts. Listen in for an in-depth discussion on how Cuvrior is setting a new standard in the management of Wilson disease, providing hope for patients seeking effective, accessible, and safe treatment options. There is also a new assay in development for nonceruloplasmin copper concentration that will help with patient management (research update to follow).
Be sure to send any questions to Dr. Gish via email [email protected] or via his website www.robertgish.com. Thank you for listening!
By Robert G Gish MDJoin Dr. Robert Gish in this insightful episode as he discusses the latest breakthrough in Wilson disease treatment: Cuvrior. This innovative medication offers a new option for patients with Wilson disease, featuring a remarkable safety profile, the convenience of no refrigeration, and future possibility of once-a-day dosing (research in progress). Dr. Gish explores how Cuvrior is revolutionizing care with its potential to be more affordable than traditional treatments like trientine, depending on insurance and contracts. Listen in for an in-depth discussion on how Cuvrior is setting a new standard in the management of Wilson disease, providing hope for patients seeking effective, accessible, and safe treatment options. There is also a new assay in development for nonceruloplasmin copper concentration that will help with patient management (research update to follow).
Be sure to send any questions to Dr. Gish via email [email protected] or via his website www.robertgish.com. Thank you for listening!